Milestone Pharmaceuticals (MIST) Competitors $1.84 -0.01 (-0.54%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MIST vs. VERU, SBBP, SLGL, TKNO, ALEC, CTNM, AMLX, FDMT, VALN, and KMDAShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Veru (VERU), Strongbridge Biopharma (SBBP), Sol-Gel Technologies (SLGL), Alpha Teknova (TKNO), Alector (ALEC), Contineum Therapeutics (CTNM), Amylyx Pharmaceuticals (AMLX), 4D Molecular Therapeutics (FDMT), Valneva (VALN), and Kamada (KMDA). These companies are all part of the "medical" sector. Milestone Pharmaceuticals vs. Veru Strongbridge Biopharma Sol-Gel Technologies Alpha Teknova Alector Contineum Therapeutics Amylyx Pharmaceuticals 4D Molecular Therapeutics Valneva Kamada Veru (NASDAQ:VERU) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability. Which has more volatility and risk, VERU or MIST? Veru has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500. Do insiders & institutionals believe in VERU or MIST? 47.2% of Veru shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Comparatively, 9.9% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better valuation & earnings, VERU or MIST? Milestone Pharmaceuticals has lower revenue, but higher earnings than Veru. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeru$16.30M6.06-$93.15M-$0.48-1.41Milestone Pharmaceuticals$1M98.13-$59.69M-$0.81-2.27 Does the MarketBeat Community believe in VERU or MIST? Veru received 190 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. Likewise, 69.67% of users gave Veru an outperform vote while only 69.23% of users gave Milestone Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVeruOutperform Votes27169.67% Underperform Votes11830.33% Milestone PharmaceuticalsOutperform Votes8169.23% Underperform Votes3630.77% Do analysts prefer VERU or MIST? Veru presently has a consensus target price of $4.00, suggesting a potential upside of 492.59%. Milestone Pharmaceuticals has a consensus target price of $12.00, suggesting a potential upside of 552.17%. Given Milestone Pharmaceuticals' higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Veru.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Milestone Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer VERU or MIST? In the previous week, Milestone Pharmaceuticals' average media sentiment score of 0.90 beat Veru's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Veru Neutral Milestone Pharmaceuticals Positive Is VERU or MIST more profitable? Milestone Pharmaceuticals has a net margin of 0.00% compared to Veru's net margin of -376.38%. Veru's return on equity of -115.99% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Veru-376.38% -115.99% -66.94% Milestone Pharmaceuticals N/A -151.82%-49.85% SummaryMilestone Pharmaceuticals beats Veru on 8 of the 15 factors compared between the two stocks. Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.13M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-2.2711.10105.1417.83Price / Sales98.13362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book4.0910.377.096.50Net Income-$59.69M$153.60M$119.65M$226.22M7 Day Performance8.24%4.60%2.25%4.03%1 Month Performance25.17%-6.29%-2.33%4.92%1 Year Performance-30.57%33.41%33.98%29.30% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals2.4553 of 5 stars$1.84-0.5%$12.00+552.2%-30.6%$98.13M$1M-2.2730VERUVeru1.7197 of 5 stars$0.68+8.0%$4.00+492.6%-30.9%$98.81M$16.30M-1.31189SBBPStrongbridge BiopharmaN/A$2.00flatN/A+0.0%$135.66M$30.73M-2.5672Gap DownSLGLSol-Gel Technologies3.6434 of 5 stars$0.53+12.7%$5.00+836.3%-61.7%$14.88M$11.71M-1.5350News CoverageGap UpTKNOAlpha Teknova0.7094 of 5 stars$7.33+0.7%$5.00-31.8%+262.9%$390.76M$36.68M-9.91240Gap DownALECAlector4.2033 of 5 stars$3.94+4.8%$20.67+424.5%-18.6%$385.84M$97.06M-2.32270CTNMContineum Therapeutics1.6486 of 5 stars$14.09-1.7%$29.25+107.6%N/A$363.21M$50M0.0031AMLXAmylyx Pharmaceuticals4.193 of 5 stars$5.27+1.5%$11.43+116.9%-58.5%$361.26M$380.79M-1.38200Gap UpFDMT4D Molecular Therapeutics3.0273 of 5 stars$7.79-2.5%$42.13+440.8%-35.7%$360.13M$20.72M-2.73201Analyst ForecastNews CoverageVALNValneva2.3222 of 5 stars$4.43+0.2%$18.50+317.6%-63.3%$359.94M$165.52M-34.08700KMDAKamada3.8019 of 5 stars$5.87+0.3%$14.50+147.0%+23.6%$337.41M$142.52M20.96360 Related Companies and Tools Related Companies VERU Alternatives SBBP Alternatives SLGL Alternatives TKNO Alternatives ALEC Alternatives CTNM Alternatives AMLX Alternatives FDMT Alternatives VALN Alternatives KMDA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MIST) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIST Stock Alerts